» Articles » PMID: 29875280

Passenger Mutations Can Accelerate Tumour Suppressor Gene Inactivation in Cancer Evolution

Overview
Date 2018 Jun 8
PMID 29875280
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Carcinogenesis is an evolutionary process whereby cells accumulate multiple mutations. Besides the 'driver mutations' that cause the disease, cells also accumulate a number of other mutations with seemingly no direct role in this evolutionary process. They are called passenger mutations. While it has been argued that passenger mutations render tumours more fragile due to reduced fitness, the role of passenger mutations remains understudied. Using evolutionary computational models, we demonstrate that in the context of tumour suppressor gene inactivation (and hence fitness valley crossing), the presence of passenger mutations can accelerate the rate of evolution by reducing overall population fitness and increasing the relative fitness of intermediate mutants in the fitness valley crossing pathway. Hence, the baseline rate of tumour suppressor gene inactivation might be faster than previously thought. Conceptually, parallels are found in the field of turbulence and pattern formation, where instabilities can be driven by perturbations that are damped (disadvantageous), but provide a richer set of pathways such that a system can achieve some desired goal more readily. This highlights, through a number of novel parallels, the relevance of physical sciences in oncology.

Citing Articles

Podoplanin expression in various types of oral dysplasia and oral squamous cell carcinoma.

Mashhadiabbas F, Chafjiri M, Dashti M, Mudasser M, Gholami S J Taibah Univ Med Sci. 2025; 20(1):40-51.

PMID: 39866370 PMC: 11761884. DOI: 10.1016/j.jtumed.2024.11.007.


CDMPred: a tool for predicting cancer driver missense mutations with high-quality passenger mutations.

Wang L, Sun H, Yue Z, Xia J, Li X PeerJ. 2024; 12:e17991.

PMID: 39253604 PMC: 11382650. DOI: 10.7717/peerj.17991.


Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives.

Shi X, Wang X, Yao W, Shi D, Shao X, Lu Z Signal Transduct Target Ther. 2024; 9(1):192.

PMID: 39090094 PMC: 11294630. DOI: 10.1038/s41392-024-01885-2.


Plasminogen missense variants and their involvement in cardiovascular and inflammatory disease.

Brito-Robinson T, Ayinuola Y, Ploplis V, Castellino F Front Cardiovasc Med. 2024; 11:1406953.

PMID: 38984351 PMC: 11231438. DOI: 10.3389/fcvm.2024.1406953.


Variant Allele Frequency Analysis of Circulating Tumor DNA as a Promising Tool in Assessing the Effectiveness of Treatment in Non-Small Cell Lung Carcinoma Patients.

Galant N, Nicos M, Kuznar-Kaminska B, Krawczyk P Cancers (Basel). 2024; 16(4).

PMID: 38398173 PMC: 10887123. DOI: 10.3390/cancers16040782.


References
1.
Durrett R, Foo J, Leder K . Spatial Moran models, II: cancer initiation in spatially structured tissue. J Math Biol. 2015; 72(5):1369-400. PMC: 4947874. DOI: 10.1007/s00285-015-0912-1. View

2.
Haber D, Settleman J . Cancer: drivers and passengers. Nature. 2007; 446(7132):145-6. DOI: 10.1038/446145a. View

3.
Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S . Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015; 348(6237):880-6. PMC: 4471149. DOI: 10.1126/science.aaa6806. View

4.
Weissman D, Desai M, Fisher D, Feldman M . The rate at which asexual populations cross fitness valleys. Theor Popul Biol. 2009; 75(4):286-300. PMC: 2992471. DOI: 10.1016/j.tpb.2009.02.006. View

5.
Carter A, Wagner G . Evolution of functionally conserved enhancers can be accelerated in large populations: a population-genetic model. Proc Biol Sci. 2002; 269(1494):953-60. PMC: 1690979. DOI: 10.1098/rspb.2002.1968. View